Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway.
Anwu HuangZhaolin WangHua TangZhuyin JiaXiaojun JiXuehua YangWenbing JiangPublished in: Cardiovascular therapeutics (2023)
BARD ameliorates myocardial I/R injury by inhibiting oxidative stress and cardiomyocyte apoptosis via activating the Nrf2/HO-1 pathway.